Related Experiment Video
Updated: Aug 23, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing
Yelena Mirochnik1, Marvin Rubenstein, Patrick Guinan
1Division of Cellular Biology, The Hektoen Institute for Medical Research, and Department of Biochemistry, Rush Presbyterian St. Lukes Medical Center, Chicago, Illinois 60612, USA.
Abstract:
We evaluated the ability of antibody-derived delivery vehicles (DVs) to direct synthetic biotinylated oligodeoxynucleotides (ODNs) to prostate tumors in vitro. A monoclonal mouse antibody raised against prostate-specific antigen (PSA) was modified by two approaches to produce either: (1) a bispecific delivery vehicle recognizing both PSA and biotin (DV(Hc)), or (2) an avidin-conjugated anti-PSA delivery vehicle (DV(PSA)). Immunoreactivity of the DVs and their ability to form complexes were tested in vitro. Although both DVs retained immunoreactivity and were able to form complexes with biotinylated ODNs, the avidin modification method was more efficient. This method may be useful for selective delivery of antisense ODNs to prostate tumors.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

